Navigation Links
First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment

BOSTON, May 01, 2007 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today new data, which show that immediate initiation(1) of Betaseron(R) (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent(2) over three years compared to delayed treatment(3). These findings from the BENEFIT (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment) studies(4) were presented today at the American Academy of Neurology's 59th Annual Meeting in Boston, Massachusetts.

"Some patients have already developed significant neurological damage when they first present with signs of MS, which can lead to accumulated disability later in life. The BENEFIT results clearly show that immediate treatment with Betaseron initiated after the first clinical event can significantly reduce that damage, which could translate into a greater delay in the time it takes for patients to suffer from the debilitating consequences of MS," said Dr. Mark S. Freedman, Professor of Neurology at the University of Ottawa and investigator of the study. "This is a truly novel finding that has not yet been demonstrated for any other immunomodulatory MS treatment, and underscores the urgent need to treat patients early, rather than waiting for further signs of MS to develop. Physicians and patients should consider these unprecedented findings when making treatment decisions."

"We are delighted that the BENEFIT study continues to deliver groundbreaking results," said Darlene Jody, M.D., Senior Vice President and President, of Bayer Healthcare's Specialized Therapeutics Global Business Unit. "In the past year, Betaseron has received approval around the world f
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/26/2014)... DIEGO , Aug. 26, 2014  Sorrento ... a late-stage clinical oncology company developing new treatments ... that it has received funding to advance an ... potential treatment of IPF, which affects more than ... the lungs increases and patients gradually lose the ...
(Date:8/26/2014)... , Aug. 26, 2014 MNX ... that it has renewed a multi-year contract providing ... the third largest spinal device company in the ... medical device industry is well suited to MNX,s ... that every shipment involves a surgeon, surgical team ...
(Date:8/26/2014)... DIEGO , Aug. 26, 2014 Profil ... research organization (CRO) focused on diabetes and obesity, announced ... completion of more than 200 phase I – IIa ... the treatment of type 1 and type 2 diabetes. ... of research is what it represents for the public ...
Breaking Medicine Technology:Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3MNX Global Logistics renews multi-year contract with NuVasive, Inc. 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 3
... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
(Date:8/27/2014)... 2014 AvePoint, the ... software solutions for next-generation social collaboration platforms, announced ... 500|5000, an exclusive ranking of the nation’s fastest-growing ... joins brands such as Alex and Ani, Gazelle, ... , This underscores continued growth and expansion for ...
(Date:8/27/2014)... 27, 2014 Discover Leadership Training is ... corporate transformation through their comprehensive leadership programs. As the ... unparalleled experience in the realm of outcome-focused and benefit-driven ... in a new webinar series titled, “A Women’s Guide ... first of this two part webinar is titled, “My ...
(Date:8/27/2014)... is one of the most loved online bamboo product suppliers; ... now. Recently, it has announced its new selection of ... strives to offer one-stop shopping solutions for people who want ... it is providing big discounts for all the brand new ... a discounted price (up to 30% off) before the deadline ...
(Date:8/27/2014)... Overcoming a turbulent past which branded KC Armstrong as ... Radio Network, WRNW1, has recently signed a multi-million dollar contract ... the WRNW1 family. KC states, “it is such a great ... After KC Armstrong publicly announced his appreciation to Howard Stern, ... “Howard 100 News,” have decided to pay it forward. , ...
(Date:8/27/2014)... 27, 2014 AttorneyOne.com, a recognized authority ... latest information from the FDA on Organic Raw ... 1, that Organic Raw Carob Powder sold from March ... due to possible contamination with Salmonella. , Salmonella ... immune systems. In healthy people it can cause abdominal ...
Breaking Medicine News(10 mins):Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Barb Moses, Vice President of Discover Leadership Training, Announces New Webinar Titled, “A Women’s Guide to Making Her Life Story a Bestseller” 2Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Organic Raw Carob Powder by Sunburst SuperFoods Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Reporter , MONDAY, Feb. 7 (HealthDay News) -- Babies ... were 4 months old were more likely to be obese ... solid foods didn,t increase the odds of becoming obese in ... breast-fed -- or who stopped breast-feeding before the age of ...
... and Emilio Botn, president of Banco Santander have ... in Boadilla del Monte) the new facilities for ... (Progression of Early Subclinical Atherosclerosis) CNIC-Santander study. The ... Research (CNIC) and Grupo Santander is aimed at ...
... The majority of fatal cases of malaria are caused ... at risk are young children and women who are pregnant. ... National Institutes of Health, Rockville, has now developed an approach ... way that they are able to identify parasite genes associated ...
... cause of many diseases. Gene therapy direct replacement of ... of correcting such defects. Now a research team based at ... by Privatdozent Dr. Carsten Rudolph, has taken a new approach ... time that chemical modification of mRNAs (the metabolically active molecules ...
... A digital signal processing technique long used by statisticians ... roots of memory and learning, Alzheimer,s and Parkinson,s diseases ... University of Texas Health Science Center at Houston (UTHealth) ... that single molecule fluorescence resonance energy transfer (FRET) ...
... levels and menstrual bleeding pattern in women with polycystic ... Gothenburg, Sweden., PCOS is a common disorder that affects ... Women with PCOS frequently have irregular ovulation and menstruation, ... This causes the ovaries to produce more testosterone which, ...
Cached Medicine News:Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 2Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 3Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 2Health News:CNIC and Grupo Santander present a new venue for imaging tests included in PESA study 3Health News:JCI online early table of contents: Feb. 7, 2011 2Health News:JCI online early table of contents: Feb. 7, 2011 3Health News:JCI online early table of contents: Feb. 7, 2011 4Health News:JCI online early table of contents: Feb. 7, 2011 5Health News:JCI online early table of contents: Feb. 7, 2011 6Health News:JCI online early table of contents: Feb. 7, 2011 7Health News:Save messengers -- modified mRNAs open up new therapeutic possibilities 2Health News:Researchers get a grip on nervous system's receptors 2Health News:Researchers get a grip on nervous system's receptors 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: